Neuland Laboratories Reports Q2 Earnings and New Capex Plan

Revenue from operations stood at Rs 449.66 crore; Net profit for the quarter was Rs 51.63 crore.

Reader Takeaway: Q2 earnings show a year-over-year decline, while new land acquisition signals a long-term growth strategy for capacity.

What just happened

Neuland Laboratories released its unaudited financial results for the second quarter and half-year ended September 30, 2026. The company posted a consolidated revenue of Rs 449.66 crore compared to Rs 514.27 crore in the same quarter last year. Net profit was reported at Rs 51.63 crore, down from Rs 96.85 crore in Q2 FY2026. Basic earnings per share (EPS) for the quarter stood at Rs 40.24, significantly lower than the Rs 75.49 recorded in the previous year's comparable quarter.

Why this matters

The decline in top-line and bottom-line numbers reflects a challenging operational environment compared to the previous fiscal year. However, the Board has initiated a capital expenditure plan of Rs 47.1 crore to acquire land in Sangareddy District, Telangana. This land acquisition is earmarked for future capacity expansion, which the company intends to fund entirely through internal accruals.

Risks to watch

Investors should closely track the execution of the capacity expansion project. Given the current dip in profitability, the company's ability to maintain margins while funding new growth through internal accruals remains a primary point of focus. Market participants will also watch for signs of demand recovery in upcoming quarters.

What to track next

Watch for updates on the completion of the land acquisition in Domadugu Village and the subsequent timeline for setting up new manufacturing or operational facilities at the site. Future earnings calls will likely provide clarity on when this added capacity is expected to contribute to the company's revenue stream.